Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Acoustic Pressure Helps Deliver Drugs to the Brain

By BiotechDaily International staff writers
Posted on 26 Aug 2014
Image: Fluorescence images of the murine hippocampus after diffusion of Dextran through the FUS opened BBB (Left), compared to contralateral that shows no uptake (Right) (Photo courtesy of Dr. Elisa Konofagou/ Columbia University).
Image: Fluorescence images of the murine hippocampus after diffusion of Dextran through the FUS opened BBB (Left), compared to contralateral that shows no uptake (Right) (Photo courtesy of Dr. Elisa Konofagou/ Columbia University).
A new technique uses a focused ultrasound (FUS) beam to control the size of molecules penetrating the blood-brain barrier (BBB).

Researchers at Columbia University (New York, NY, USA) conducted a study that applied FUS onto a mouse hippocampus in the presence of systemically administered microbubbles (MBs) containing fluorescently labeled dextrans with molecular weights of 3-2,000 kDa (2.3–54.4 nm in diameter), to examine the possibility of trans-BBB dextran delivery. Outcomes were evaluated using ex vivo fluorescence imaging, and cavitation detection was employed to concomitantly monitor the MB activity associated with the delivery of the dextrans.

The results showed that FUS-induced BBB opening size—defined by the size of the largest molecule that can permeate through the BBB—can be controlled by acoustic pressure. BBB opening size was smaller than 3 kDa (2.3 nm) at 0.31 MPa, reached 70 kDa (10.2 nm) at 0.51 MPa, and was as large as 2,000 kDa (54.4 nm) at 0.84 MPa. Relatively smaller opening size (up to 70 kDa) was achieved with stable cavitation only; however, inertial cavitation was associated with relatively larger BBB opening size (above 500 kDa). The study was published in the July 2014 issue of the Journal of Cerebral Blood Flow & Metabolism.

“Most small and all large molecule drugs do not currently penetrate the blood-brain barrier that sits between the vascular bed and the brain tissue,” said study coauthor professor of biomedical engineering and radiology Elisa Konofagou, PhD, of Columbia Engineering. “This is an important breakthrough in getting drugs delivered to specific parts of the brain precisely, noninvasively, and safely, and may help in the treatment of central nervous system diseases like Parkinson's and Alzheimer's.”

FUS in conjunction with MBs—gas-filled bubbles coated by protein or lipid shells—is so far the only technique can permeate the BBB safely and noninvasively. When MBs are hit by an FUS beam, they start oscillating due to cavitation, the formation of vapor cavities in the liquid phase; depending on the magnitude of the pressure, they continue oscillating or collapse. The study showed that the pressure of the FUS can be adjusted depending on the size of the drug that needs to be delivered to the brain - small molecules at lower pressures and larger molecules at higher pressures.

Related Links:

Columbia University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.